Roivant Sciences Ltd. — Form 10-Q Summary
Period clarification: The request metadata says 2021 Q3, but this filing covers the fiscal quarter and nine months ended December 31, 2022 (Roivant fiscal 2023 Q3). Figures below are unaudited and in U.S. dollars; financial statement amounts are converted from thousands to millions where shown.
Business context and reporting period
Roivant develops and commercializes medicines through subsidiary companies known as Vants, alongside healthcare technology and drug-discovery businesses. VTAMA (tapinarof) was its first commercial product, FDA-approved for adult plaque psoriasis in May 2022. The filing reports one consolidated operating segment.
Financial performance and position
| Metric | Three months ended Dec. 31, 2022 | Three months ended Dec. 31, 2021 | Nine months ended Dec. 31, 2022 | Nine months ended Dec. 31, 2021 |
|---|---|---|---|---|
| Revenue, net | $17.1m | $24.3m | $33.9m | $46.1m |
| Operating loss | $(378.1)m | $(246.0)m | $(941.2)m | $(1,084.8)m |
| Net loss | $(384.9)m | $(306.1)m | $(1,054.6)m | $(632.8)m |
| Net loss attributable to Roivant | $(352.0)m | $(284.5)m | $(975.4)m | $(575.2)m |
| Net loss per share, basic and diluted | $(0.49) | $(0.41) | $(1.39) | $(0.87) |
| Operating cash flow | Not presented by quarter | $(664.3)m | $(530.3)m |
For the December 2022 quarter, revenue included $9.2m of VTAMA product sales; nine-month VTAMA revenue was $14.4m. Cost of revenues was $3.6m for the quarter and $9.0m for nine months. Simple consolidated gross profit (revenue less cost of revenues) was $13.5m and $25.0m, respectively; these figures include licensing and other revenue as well as product revenue.
At December 31, 2022, cash and cash equivalents were $1,527.4m; cash, cash equivalents and restricted cash totaled $1,541.0m. Current assets were $1,646.2m and current liabilities $244.3m. Total assets were $2,203.0m and total liabilities $775.8m. Long-term debt, including current portions, was approximately $412.8m. Accumulated deficit was $3,739.1m. Nine-month financing cash flow was $289.1m and investing cash flow was $(157.8)m.
Material changes versus prior comparable periods
- Quarterly revenue fell $7.3m year over year, as VTAMA sales of $9.2m were more than offset by lower license, milestone and other revenue. Nine-month revenue declined $12.2m for similar reasons.
- Quarterly operating loss widened by $132.1m, reflecting $81.6m more acquired in-process R&D expense and $52.7m higher SG&A, partly offset by lower R&D. SG&A rose with VTAMA commercialization.
- Nine-month operating loss improved by $143.7m, principally because prior-year SG&A included a one-time $350.0m share-based compensation catch-up charge following the 2021 business combination. The improvement was partly offset by higher R&D and lower revenue.
- Nine-month net loss increased by $421.8m. The prior-year period included a $443.8m gain on the Datavant transaction and a $66.5m gain on termination of Sumitomo options, neither repeated in 2022; 2022 also included $29.3m of gains on deconsolidation of subsidiaries.
- Nine-month operating cash use increased by $134.0m, which management attributed mainly to funding advancing clinical programs and the VTAMA launch. Cash and cash equivalents declined from $2,060.4m at March 31, 2022 to $1,527.4m at December 31, 2022.
Outlook, management commentary, risks and unusual items
- Management said existing cash was expected to cover committed operating and capital needs for at least 12 months from the financial statements’ issuance. Pro forma for the February 2023 share offering and anticipated Myovant-related proceeds, management estimated cash, cash equivalents and restricted cash of about $1.9bn and runway into the second half of calendar 2025. These estimates depend on assumptions and may prove inaccurate.
- In February 2023, Roivant completed an offering of 30.7m shares at $7.50, for $230m gross proceeds before fees. Roivant also expected approximately $114.5m from the anticipated Myovant transaction, which was expected to close in the quarter ending March 31, 2023, subject to customary conditions.
- Management expects R&D and commercialization costs to rise as it advances its pipeline and expands VTAMA commercial operations. It expects continued operating losses and may need additional capital; financing may dilute shareholders or be unavailable on acceptable terms.
- In November 2022, Roivant licensed RVT-3101, a TL1A antibody, from Pfizer through a new Vant. Roivant’s Vant holds U.S. and Japan commercialization rights and is responsible for worldwide development; Pfizer retains commercialization rights elsewhere. The filing recorded $87.7m of acquired IPR&D expense for the transaction. The Vant also has an option to collaborate on a next-generation TL1A antibody.
- Dermavant paid approximately $126m to GSK and $20m to Welichem for VTAMA-related milestones in 2022. It received $160m under a revenue-interest financing arrangement, under which it owes a capped single-digit revenue interest on U.S. tapinarof sales, up to $344m.
- Roivant reported preliminary TUSCANY-2 Phase 2b induction results for RVT-3101 in ulcerative colitis, including statistically significant efficacy at tested doses and a favorable reported safety profile. The company cautions that interim or top-line results can change after full analysis and verification.
- Key risks include commercialization and payer access for VTAMA, uncertain clinical and regulatory outcomes, reliance on third-party manufacturers, future financing needs, competition, and intellectual-property disputes. The filing notes that VTAMA lacks issued composition-of-matter patents. A securities lawsuit naming Immunovant and Roivant remains pending; Roivant said it could not reasonably estimate potential losses. An Acuitas declaratory judgment action involving Genevant and Arbutus is also ongoing.
- Management concluded disclosure controls and procedures were effective as of December 31, 2022; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Confirm the intended reporting period: this is fiscal 2023 Q3, not 2021 Q3.
- Track VTAMA prescriptions, net sales, payer coverage, gross-to-net deductions and commercial spending; confirm whether launch momentum translates into durable revenue and margins.
- Monitor actual cash burn, debt and revenue-interest obligations, and whether the anticipated Myovant proceeds and stated cash-runway assumptions are realized.
- Review final RVT-3101 data and development plans, as well as upcoming clinical results and any changes to catalyst timing.
- Assess the outcome and potential financial exposure of the Immunovant securities litigation and the Genevant/Arbutus patent disputes.
- Evaluate dilution from equity offerings, subsidiary financings and outstanding equity awards, and the effect of fair-value changes in investments and liabilities on reported earnings.